Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) EBT Margin (2021 - 2025)

Krystal Biotech's EBT Margin history spans 4 years, with the latest figure at 47.74% for Q4 2025.

  • For Q4 2025, EBT Margin fell 560.0% year-over-year to 47.74%; the TTM value through Dec 2025 reached 48.69%, up 1587.0%, while the annual FY2025 figure was 48.69%, 1587.0% up from the prior year.
  • EBT Margin for Q4 2025 was 47.74% at Krystal Biotech, down from 49.05% in the prior quarter.
  • Across five years, EBT Margin topped out at 1059.79% in Q1 2021 and bottomed at 2.06% in Q1 2024.
  • The 4-year median for EBT Margin is 48.72% (2025), against an average of 212.5%.
  • The largest annual shift saw EBT Margin plummeted -90824bps in 2024 before it soared 4737bps in 2025.
  • A 4-year view of EBT Margin shows it stood at 1059.79% in 2021, then crashed by -98bps to 25.29% in 2023, then skyrocketed by 111bps to 53.34% in 2024, then decreased by -11bps to 47.74% in 2025.
  • Per Business Quant, the three most recent readings for KRYS's EBT Margin are 47.74% (Q4 2025), 49.05% (Q3 2025), and 48.72% (Q2 2025).